Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

Timothy Iveson; Ross C Donehower; Irina Davidenko; Sergey Tjulandin; Andrzej Deptala; Mark Harrison; Somanath Nirni; Kuntegowdanahalli Lakshmaiah; Anne Thomas; Yizhou Jiang; Min Zhu; Rui Tang; Abraham Anderson; Sarita Dubey; Kelly S Oliner; Elwyn Loh

doi:10.1016/s1470-2045(14)70023-3

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)70023-3 ◽

2014 ◽

Vol 15 (9) ◽

pp. 1007-1018 ◽

Cited By ~ 177

Author(s):

Timothy Iveson ◽

Ross C Donehower ◽

Irina Davidenko ◽

Sergey Tjulandin ◽

Andrzej Deptala ◽

...

Keyword(s):

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Double Blind ◽

Oesophagogastric Junction ◽

Phase 2 Study ◽

Label Dose ◽

Phase 1B ◽

First Line Treatment

Download Full-text

Abstract C122: A randomized, multicenter, open-label, phase 2 study of paclitaxel-carboplatin (PC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus PC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

10.1158/1535-7163.targ-15-c122 ◽

2015 ◽

Author(s):

David Spigel ◽

Alexander Luft ◽

Rodryg Ramlau ◽

Mazen Khalil ◽

Joo-Hang Kim ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine (Gem) and cisplatin (Cis) in the first-line treatment of patients with advanced solid tumors: Preliminary results of a phase IB study

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.2103 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 2103-2103 ◽

Cited By ~ 4

Author(s):

J. Voortman ◽

E. F. Smit ◽

B. C. Kuenen ◽

H. M. Pinedo ◽

C. van Groeningen ◽

...

Keyword(s):

Dose Escalation ◽

Advanced Solid Tumors ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Dose Escalation Study ◽

Phase Ib ◽

Label Dose ◽

Phase 1B ◽

First Line Treatment

Download Full-text

A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer

Annals of Oncology ◽

10.1093/annonc/mds505 ◽

2013 ◽

Vol 24 (2) ◽

pp. 329-336 ◽

Cited By ~ 47

Author(s):

A. Heidenreich ◽

S.K. Rawal ◽

K. Szkarlat ◽

N. Bogdanova ◽

L. Dirix ◽

...

Keyword(s):

Human Monoclonal Antibody ◽

Line Treatment ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

First Line ◽

Double Blind ◽

Castration Resistant ◽

Multicenter Phase ◽

Phase 2 Study ◽

First Line Treatment

Download Full-text

Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study

The Lancet Haematology ◽

10.1016/s2352-3026(18)30131-5 ◽

2018 ◽

Vol 5 (9) ◽

pp. e403-e410 ◽

Cited By ~ 9

Author(s):

Hervé Tilly ◽

Franck Morschhauser ◽

Olivier Casasnovas ◽

Thierry Jo Molina ◽

Pierre Feugier ◽

...

Keyword(s):

Follicular Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

Tumour Burden ◽

First Line ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

1468 POSTER A phase 1B, open-label, dose-escalation study of bortezomib (Btz) in combination with gemcitabine (G) and cisplatin (C) in the first-line treatment of patients with advanced solid tumors: preliminary results

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81759-8 ◽

2005 ◽

Vol 3 (2) ◽

pp. 425

Keyword(s):

Solid Tumors ◽

Dose Escalation ◽

Advanced Solid Tumors ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Dose Escalation Study ◽

Label Dose ◽

Phase 1B ◽

First Line Treatment

Download Full-text

PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck

Oral Oncology ◽

10.1016/j.oraloncology.2016.07.005 ◽

2016 ◽

Vol 61 ◽

pp. 31-40 ◽

Cited By ~ 14

Author(s):

Lori J. Wirth ◽

Shaker Dakhil ◽

Gabriela Kornek ◽

Rita Axelrod ◽

Douglas Adkins ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Study ◽

Metastatic Squamous Cell Carcinoma ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

A single-arm, open-label, phase 2 study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdw383.98 ◽

2016 ◽

Vol 27 ◽

pp. vi454 ◽

Cited By ~ 1

Author(s):

M. Socinski ◽

M. Gil ◽

J. Shahidi ◽

G.Y. Chao ◽

L. Villaruz

Keyword(s):

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

The Lancet Oncology ◽

10.1016/s1470-2045(11)70037-7 ◽

2011 ◽

Vol 12 (4) ◽

pp. 369-376 ◽

Cited By ~ 64

Author(s):

Miguel Martin ◽

Henri Roche ◽

Tamas Pinter ◽

John Crown ◽

M John Kennedy ◽

...

Keyword(s):

Metastatic Breast ◽

Controlled Study ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve

Bulletin du Cancer ◽

10.1016/s0007-4551(20)30280-0 ◽

2020 ◽

Vol 107 (5) ◽

pp. eS1-eS7

Author(s):

Marine Gross-Goupil ◽

Charlotte Domblides ◽

Felix Lefort ◽

Alain Ravaud

Keyword(s):

Bladder Carcinoma ◽

Locally Advanced ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Urothelial Bladder Carcinoma ◽

Phase 2 Study ◽

Urothelial Bladder ◽

First Line Treatment

Download Full-text

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text